Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nimodipine microparticles - PDS Biotechnology Corporation

Next Previous
Search
Drug Profile

Nimodipine microparticles - PDS Biotechnology Corporation

Alternative Names: EG-1962; NimoVent; Polymeric nimodipine microparticle

Latest Information Update: 25 Nov 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Edge Therapeutics
  • Developer PDS Biotechnology Corporation
  • Class Antihaemorrhagics; Antihypertensives; Dihydropyridines; Esters; Nicotinic acids; Small molecules
  • Mechanism of Action Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Subarachnoid haemorrhage
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cerebral ischaemia

Most Recent Events

  • 18 Mar 2019 PDS Biotechnology Corporation merged with Edge Therapeutics to form PDS Biotechnology Corporation
  • 27 Jun 2018 Efficacy data from a phase III NEWTON 2 trial in Cerebral ischaemia released by Edge Therapeutics
  • 04 Apr 2018 Edge Therapeutics terminates a phase I trial in Cerebral ischaemia (Prevention) in USA (Intracisternal) (NCT02893826)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top